Model Organisms in Drug Discovery

220 LIPID METABOLISM AND SIGNALING IN ZEBRAFISH
Haffter, P., Granato, M., Brand, M., Mullins, M. C., Hammerschmidt, M., Kane, D. A.,
Odenthal, J., et al. (1996). The identification of genes with unique and essential functions
in the development of the zebrafish, Danio rerio. Development 123, 1–36.
Hendrickson, H. S., Hendrickson, E. K., Johnson, I. D. and Farber, S. A. (1999).
Intramolecularly quenched BODIPY-labeled phospholipid analogs in phospholipase
A(2) and platelet-activating factor acetylhydrolase assays and in vivo fluorescence
imaging. Anal. Biochem. 276, 27–35.
Hennekens, C. H. (2001). Current perspectives on lipid lowering with statins to decrease
risk of cardiovascular disease. Clin. Cardiol. 24(7 Suppl), II-2–5.
Jagadeeswaran, P. and Sheehan, J. P. (1999). Analysis of blood coagulation in the
zebrafish. Blood Cells Mol. Dis. 25, 239–249.
Jiang, C., Ting, A. T. and Seed, B. (1998). PPAR-gamma agonists inhibit production of
monocyte inflammatory cytokines. Nature 391, 82–86.
Joffe, B. I., Panz, V. R. and Raal, F. J. (2001). From lipodystrophy syndromes to diabetes
mellitus. Lancet 357, 1379–1381.
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C. and Lehmann, J. M.
(1995). A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor
gamma and promotes adipocyte differentiation. Cell 83, 813–819.
Knopp, R. H. (1999). Drug treatment of lipid disorders. N. Engl. J. Med. 341, 498–511.
Langenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada,
P. C., Mahler, J. F., et al. (1995). Prostaglandin synthase 1 gene disruption in mice
reduces arachidonic acid-induced inflammation and indomethacin-induced gastric
ulceration. Cell 83, 483–492.
Liu, Y. W. and Chan, W. K. (2002). Thyroid hormones are important for embryonic to
larval transitory phase in zebrafish. Differentiation 70, 36–45.
MacPhee, M., Chepenik, K. P., Liddell, R. A., Nelson, K. K., Siracusa, L. D. and
Buchberg, A. M. (1995). The secretory phospholipase A2 gene is a candidate for the
Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81, 957–966.
Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler,
M. R., et al. (2002). Vitamin D receptor as an intestinal bile acid sensor. Science 296,
1313–1316.
Mancini, J. A., Vickers, P. J., O’Neill, G. P., Boily, C., Falgueyret, J. P. and Riendeau, D.
(1997). Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to
inhibition by nonsteroidal anti-inflammatory drugs. Mol. Pharmacol. 51, 52–60.
Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M.,
Edwards, D. A., et al. (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2
inhibitors. Cancer Res. 60, 1306–1311.
McCallum, C. M., Comai, L., Greene, E. A. and Henikoff, S. (2000). Targeting induced
local lesions IN genomes (TILLING) for plant functional genomics. Plant Physiol. 123,
439–442.
McNeely, M. J., Edwards, K. L., Marcovina, S. M., Brunzell, J. D., Motulsky, A. G. and
Austin, M. A. (2001). Lipoprotein and apolipoprotein abnormalities in familial
combined hyperlipidemia: a 20-year prospective study. Atherosclerosis 159, 471–481.
Morham, S. G., Langenbach, R., Loftin, C. D., Tiano, H. F., Vouloumanos, N., Jennette,
J. C., Mahler, J. F., et al. (1995). Prostaglandin synthase 2 gene disruption causes severe
renal pathology in the mouse. Cell 83, 473–482.
Narumiya, S. and FitzGerald, G. A. (2001). Genetic and pharmacological analysis of
prostanoid receptor function. J. Clin. Invest. 108, 25–30.
Pajukanta, P. and Porkka, K. V. (1999). Genetics of familial combined hyperlipidemia.
Curr. Atheroscler. Rep. 1, 79–86.